Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.

The Journal of clinical investigation - 1 Mar 2011

Gelb Bruce D, Tartaglia Marco

Abstract excerpt

In this issue of the JCI, Wu et al. and Marin et al. describe two new mouse models of inherited disorders of the RAS/MAPK signal transduction pathway that display hypertrophic cardiomyopathy (HCM); the model from the former paper was from a gain-of-function Raf1 mutation, and the model from the latter paper was from a protein tyrosine phosphatase, non-receptor type 11 (Ptpn11) mutated allele encoding Shp2 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy, Hypertrophic
Share to Catalysis
Share to Genes, ras

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Models, Biological

Share to Noonan Syndrome

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to ras Proteins

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 21339640
DOI: 10.1172/JCI46399
PMCID: PMC3046639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.PMID 21339640Read ↗

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.Semantic proximity Read ↗

Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies.Semantic proximity Read ↗

Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes.Semantic proximity Read ↗

MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.Semantic proximity Read ↗

RASopathies and Cardiac Complications: Insights into Mechanisms, Diagnosis, and Innovative Treatments.Semantic proximity Read ↗

RASopathies in Cardiac DiseaseSemantic proximity Read ↗

Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice <i>in vivo</i>Semantic proximity Read ↗

Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in miceSemantic proximity Read ↗

Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.Semantic proximity Read ↗

Cardiovascular Characteristics and Progressions of Hypertrophic Cardiomyopathy and Pulmonary Stenosis in RASopathy Syndrome in the Genomic Era.Semantic proximity Read ↗

Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathySemantic proximity Read ↗

Tumor Suppressor Ras-Association Domain Family 1 Isoform A Is a Novel Regulator of Cardiac HypertrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.